2,4-thiazolidinedione has been researched along with Hyperlipemia in 9 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities." | 2.42 | Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "Insulin resistance is known to unite several metabolic abnormalities." | 2.41 | Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. ( Daida, H; Sunayama, S; Watanabe, Y; Yamaguchi, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pathak, R | 1 |
| Afaq, A | 1 |
| Blonde, L | 1 |
| Tugwood, JD | 1 |
| Montague, CT | 1 |
| Gurnell, M | 1 |
| Savage, DB | 1 |
| Chatterjee, VK | 1 |
| O'Rahilly, S | 1 |
| Ayyobi, AF | 1 |
| Brunzell, JD | 1 |
| Kim, H | 1 |
| Haluzik, M | 1 |
| Gavrilova, O | 1 |
| Yakar, S | 1 |
| Portas, J | 1 |
| Sun, H | 1 |
| Pajvani, UB | 1 |
| Scherer, PE | 1 |
| LeRoith, D | 1 |
| Kasuga, M | 1 |
| Hunabiki, A | 1 |
| Morita, S | 1 |
| Sunayama, S | 1 |
| Watanabe, Y | 1 |
| Daida, H | 1 |
| Yamaguchi, H | 1 |
| Castro Cabezas, M | 1 |
| Halkes, CJ | 1 |
| Erkelens, DW | 1 |
| Legro, RS | 1 |
8 reviews available for 2,4-thiazolidinedione and Hyperlipemia
| Article | Year |
|---|---|
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; H | 2002 |
Biology and toxicology of PPARgamma ligands.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Infla | 2002 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agent | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2003 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertens | 1999 |
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Topics: Chromans; Clinical Trials as Topic; Glucose; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin R | 2000 |
Obesity and free fatty acids: double trouble.
Topics: Chylomicrons; Coronary Artery Disease; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperlipid | 2001 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
1 other study available for 2,4-thiazolidinedione and Hyperlipemia
| Article | Year |
|---|---|
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglyc | 2004 |